Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study.
about
How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studiesNeuroendocrine differentiation: The mysterious fellow of colorectal cancerRapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysisTargeting the mTOR signaling pathway in neuroendocrine tumorsSummary of emerging personalized medicine in neuroendocrine tumors: are we on track?18F-FDG and 18F-FLT-PET imaging for monitoring everolimus effect on tumor-growth in neuroendocrine tumors: studies in human tumor xenografts in miceRetrospective analysis of the clinicopathological characteristics of gastrointestinal neuroendocrine neoplasmsEfficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.Targeting cell death signaling in colorectal cancer: current strategies and future perspectives.Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.Everolimus treatment for neuroendocrine tumors: latest results and clinical potential.Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitroImpact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4.Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study
P2860
Q26750748-D48DD4C9-D806-43EB-A008-E40FDE363F2FQ26778012-66BF1CF5-AC6B-4406-9074-26A8BBE616EEQ26799757-69A50033-E052-4038-A2A0-4443D510427CQ26852089-5DDCEE39-377F-463A-BF2C-5A5BDB736B93Q28078610-D4F50715-3140-4D88-BC12-E11A2FFF9D82Q35120054-4EC599ED-0E46-4A3E-86F9-E3555487C62BQ35942994-4857F9B0-BD7B-46DC-9027-9EBF8DC6C33EQ37091117-EE76F598-A901-4F0D-82D4-216F92BDEE73Q37602717-6ED5EBB6-EEFC-4208-A579-F2BD71F0B608Q38527936-9450272B-8E60-4815-8001-BB886ED51193Q38842250-21DAF759-BF63-4401-BD5F-124FF89E54F0Q39201601-14A52E55-EA6E-4596-A459-21A6BB52CDA7Q41548629-BEE8865F-F813-494F-A695-7B85D37B7FF9Q44062774-98574FC1-E4A9-459C-9F3F-C6F3BCD0D166Q57109641-621B3954-5FD0-463B-BF7A-70E0BA329B82
P2860
Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Everolimus plus octreotide lon ...... the phase III RADIANT-2 study.
@ast
Everolimus plus octreotide lon ...... the phase III RADIANT-2 study.
@en
type
label
Everolimus plus octreotide lon ...... the phase III RADIANT-2 study.
@ast
Everolimus plus octreotide lon ...... the phase III RADIANT-2 study.
@en
prefLabel
Everolimus plus octreotide lon ...... the phase III RADIANT-2 study.
@ast
Everolimus plus octreotide lon ...... the phase III RADIANT-2 study.
@en
P2093
P2860
P1433
P1476
Everolimus plus octreotide lon ...... the phase III RADIANT-2 study.
@en
P2093
Ashok Panneerselvam
Daniel Castellano
Emilio Bajetta
Lowell B Anthony
RADIANT-2 Study Group
Stephen Saletan
Timothy Hobday
Walter Kocha
P2860
P356
10.1634/THEONCOLOGIST.2012-0263
P577
2012-12-21T00:00:00Z